Details of the Drug Therapeutic Target (DTT)

General Information of Drug Therapeutic Target (DTT) (ID: TTHRAPJ)

• DTT Name: G-protein coupled receptor C 5D (GPRC5D)
• Gene Name: GPRC5D
• DTT Type: Clinical trial target; [1]
• UniProt ID: GPC5D_HUMAN
• TTD ID: T23519
• Sequence:
  MYKDCIESTGDYFLLCDAEGPWGIILESLAILGIVVTILLLLAFLFLMRKIQDCSQWNVL
  PTQLLFLLSVLGLFGLAFAFIIELNQQTAPVRYFLFGVLFALCFSCLLAHASNLVKLVRG
  CVSFSWTTILCIAIGCSLLQIIIATEYVTLIMTRGMMFVNMTPCQLNVDFVVLLVYVLFL
  MALTFFVSKATFCGPCENWKQHGRLIFITVLFSIIIWVVWISMLLRGNPQFQRQPQWDDP
  VVCIALVTNAWVFLLLYIVPELCILYRSCRQECPLQGNACPVTAYQHSFQVENQELSRAR
  DSDGAEEDVALTSYGTPIQPQTVDPTQECFIPQAKLSPQQDAGGV
• Function: extracellular exosome, intracellular membrane-bounded organelle, plasma membrane, receptor complex, protein kinase activator activity

Molecular Interaction Atlas (MIA) of This DTT

1 Approved Drug(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Talquetamab	DMXRENI	Multiple myeloma	2A83	Approved	[2]

2 Clinical Trial Drug(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
GPRC5D CAR-T cell therapy	DM8MGSH	Multiple myeloma	2A83	Phase 1	[1]
RG6234	DMYUSOJ	Multiple myeloma	2A83	Phase 1	[3]

References

• [1] GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells. Sci Transl Med. 2019 Mar 27;11(485):eaau7746.
• [2] FDA Approved Drug Products from FDA Official Website. 2023. Application Number: 761342
• [3] Clinical pipeline report, company report or official report of Roche